Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tanaka, M.
Right arrow Articles by Sato, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, M.
Right arrow Articles by Sato, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 1039-1040
© 2002 The British Society for Antimicrobial Chemotherapy

Correspondence

Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori

Mayumi Tanaka1,*, Emiko Isogai2, Hiroshi Isogai3, Shunji Hayashi4, Kimiharu Hirose2, Koichi Kimura5, Toshiro Sugiyama6 and Kenichi Sato1

1New Product Research Laboratories I, Daiichi Pharmaceutical Co. Ltd, 16-13 Kitakasai 1-Chome, Edogawa-ku, Tokyo 134-8630; 2Department of Preventive Dentistry, Health Sciences University of Hokkaido, 5Hokkaido Institute of Technology and 6Third Department of Internal Medicine, Hokkaido University School of Medicine, Hokkaido; 3Division of Animal Experimentation, Sapporo Medical University; 4Department of Microbiology, Jichi Medical University, Japan

Sir,

Helicobacter pylori is known to be a principal cause of chronic gastritis and is associated with peptic ulcers and gastric cancer.1 Eradication of H. pylori prevents relapse of duodenal ulcers, and treatment of this infection has now become standard for patients with peptic ulcers.2 Antibacterial treatment of H. pylori commonly includes a proton pump inhibitor and two antibacterial agents such as clarithromycin, amoxicillin or metronidazole; however, the . . . [Full Text of this Article]

Footnotes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Therapeutic Advances in GastroenterologyHome page
J. P. Gisbert
Review: Second-line rescue therapy of Helicobacter pylori infection
Therapeutic Advances in Gastroenterology, November 1, 2009; 2(6): 331 - 356.
[Abstract] [PDF]

Home page
 J Antimicrob ChemotherHome page
C.-H. Kuo, H.-M. Hu, F.-C. Kuo, P.-I. Hsu, A. Chen, F.-J. Yu, P.-Y. Tsai, I.-C. Wu, S.-W. Wang, C.-J. Li, et al.
Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial
J. Antimicrob. Chemother., May 1, 2009; 63(5): 1017 - 1024.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. P. Sivalingam, S. H. Sim, L. T. Aw, and E. E. Ooi
Antibiotic susceptibility of 50 clinical isolates of Burkholderia pseudomallei from Singapore
J. Antimicrob. Chemother., November 1, 2006; 58(5): 1102 - 1103.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Steward, T. Piercy, M. S. Lever, M. Nelson, A. J. H. Simpson, and T. J. G. Brooks
Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection
J. Antimicrob. Chemother., April 1, 2005; 55(4): 523 - 527.
[Abstract] [Full Text] [PDF]